Mojia Biotech Completes Series B Financing to Advance Manufacturing of Bio-based Materials

SHANGHAI, June 22, 2022 / PRNewswire / – Mojia Biotech, a Shanghai-based leading bio-manufacturing company dedicated to sustainable development and carbon neutrality, announced the completion of an $ 80 million Series B Financing. The funds will be used to commercialize its Viridimin ™ brand of animal-feed additives, scale up manufacturing capacity for Aliphane ™ series of bio-based materials, advance its product pipeline and expand its global R&D capabilities.

Temasek led the round, with participation from LYZZ Capital, Sento Investment, existing investors Bits x Bites and Asia Green Fund, and other investors.

For over a century, the petrochemical industry has created an abundant chemical universe for daily life and industrial applications. While significantly improving our living conditions, the petroleum-based manufacturing processes have significant environmental and social challenges. To promote sustainable development, the world is under pressure needs to be supplied with a chemical and materials supply, either by feed-stock switch or renewable carbon sources, or by manufacturing process redesign incorporating the latest advances in synthetic biology.

With its proprietary platform for enzyme and metabolic engineering, Mojia Biotech is committed to transforming the chemical and polymer space. In the past few years, Mojia Biotech has developed innovative pathways to produce Viridimin ™ brand of Vitamin B5. Compared to the prevailing approaches, Mojia’s patented bio-process not only consumes less energy and emits less wastes, but also guarantees a more stable supply of Vitamin B5 due to frequent production caused by tightening environmental regulations in China. Mojia is planning to bring this state-of-the-art facility into commission in June 2022.

The second product that Mojia Biotech finds to bring to the market is Aliphane series of biopolymer products, which are extremely versatile and have great potential in coating and adhesive applications.

Ansen Chiewco-founder of Mojia Biotech, says: “Over the last decade, we have established a comprehensive R&D platform combining biology, chemistry, engineering and polymer sciences,

accumulated hands-on experiences in large-scale bio-production and built strong global commercialization capabilities. Our green technology is proving that it is possible to address environmental pollution. We greatly appreciate visionary and like-minded investors like Temasek, Asia Green Fund, Bits x Bites and LYZZ Capital in support of our mission for sustainable development and carbon neutrality. “

Joseph Zhoumanaging partner of Bits x Bites, says: “Sustainable ingredient manufacturing is a pillar for driving green economy. for Mojia Biotech to apply its technology across different chemical ingredients, and to become a leader for next-generation green chemical production. “

Bo BaiChairman and Founder of Asia Green Fund, says: “Chemical bio-manufacturing is one of today’s most dynamic fields in the chemical industry. Mojia Biotech has effectively tackled issues such as long processes, high energy consumption and environmentally polluting by-products. We are pleased to work with Mojia Biotech to promote green and cost-leading innovation in chemicals and new materials. “

About Mojia Biotech

Mojia Biotech is a fast-growing, product-focused bio-manufacturing company dedicated to the production of renewable energy sources and green processes. It has R&D activities and partnerships across the world and manufacturing facilities in China. Learn more at www.mojiabio.com.

About Temasek

Temasek is a global investment company with a net portfolio value of S $ 381 billion (RMB1.86t) for swelling 31 March 2021. Headquartered in Singapore, it has 13 offices in 9 countries around the world. The Temasek Charter defines Temasek’s three roles as Investor, Institution and Steward, which shape its ethos to do well, do right, and do good. As a provider of catalytic capital, it seeks to enable solutions to key global challenges. With sustainability at the core of all Temasek does not have any sustainable solutions for the future. Learn more at www.temasek.com.sg.

About Bits x Bites

Bits x Bites is China’s pioneer agrifood tech VC, investing in early-stage startups China. It invests across the agrifood supply chain, from precision agriculture, crop and animal health to protein alternatives and human nutrition. Learn more at www.bitsxbites.com.

About Asia Green Fund

Asia Green Fund (“AGF”) is a private equity firm, with approximately $ 2.0 billion in assets under management, which specializes in industrial and business services sectors with a focus on technology-enabled green impact investments. Founded in 2016 as Asia’s ESF impact on society. Learn more at www.asiagreenfund.com.

About LYZZ Capital

LYZZ Capital is a leading biotech investor focusing on supporting biotechnology development to solve humanity’s unmet needs in healthcare, pharmaceuticals, food supply and sustainable materials. It invests globally with offices in San DiegoUS and Shanghai, China. Learn more at www.lyzzcap.com.

Chision

Chision

View original content: https: //www.prnewswire.com/news-releases/mojia-biotech-completes-series-b-financing-to-advance-manufacturing-of-bio-based-materials-301573164.html

SOURCE Mojia Biotech

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker